Lawmakers Fight FDA's Anti-Estriol Stance

Law360, New York (May 8, 2008, 12:00 AM EDT) -- In the wake of the U.S. Food and Drug Administration's backlash against bioidentical hormone replacement drugs, lawmakers introduced a resolution Tuesday opposing the agency's policy restricting women's access to the products.

The bipartisan motion, introduced in the U.S. House of Representatives by Rep. Mike Ross (D-Ark.), is intended to express the sense of Congress that the FDA's new policy restricting women's access to medications containing estriol – a weaker form of the hormone estrogen – “does not serve the public interest” and urging the agency to...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.